• Seventh consecutive quarter of record revenue, up 45% YoY
• Successful $30M capital raising to fund global commercialisation
• Remplir sales in US, Canada and Hong Kong gaining momentum

Orthocell Limited (ASX: OCC) has released its Quarterly Report for the quarter ended 31 December 2025, highlighting key achievements including the company's seventh consecutive quarter of record revenue. The $3.2 million in quarterly revenue represents a 45% increase over the prior corresponding period, driven primarily by growing market penetration of Remplir in existing markets and initial contributions from the US market. This revenue growth demonstrates the strong commercial traction of Orthocell's portfolio of regenerative medicine products. The company also maintained a robust financial position, with cash reserves of $49.4 million as at 31 December 2025 following the successful completion of a $30 million capital raising. This provides Orthocell with significant liquidity to support the continued global commercial expansion of Remplir. Key highlights during the quarter include the continued commercialisation of Remplir in the US, where the company has now achieved the milestone of the first 100 sales, as well as progress in expanding into new international markets such as Canada and Hong Kong. Orthocell also submitted a regulatory application for the distribution of Remplir in the EU and UK markets, which represent a significant growth opportunity. Additionally, the company secured global distribution rights to the innovative PearlBone bone regeneration technology. Orthocell's CEO, Paul Anderson, expressed confidence in the company's ability to continue driving growth and executing on its global commercialisation strategy.

Orthocell reported quarterly revenue of $3.2 million in Q4 2025, up 7% on the previous quarterly record of $3.0 million in Q3 2025, and up 45.2% on the same period last year. The company maintains a strong financial position with $49.4 million in cash reserves, including $42 million in term deposits.

Orthocell is focused on the continued commercialisation of its Remplir product, with growing momentum in the US, Canada and Hong Kong markets. The company has also submitted a regulatory application for the distribution of Remplir in the EU and UK, representing a significant growth opportunity. Orthocell is well-positioned to fund its global expansion strategy with its strong cash reserves following the successful $30 million capital raising.